SpectraScience Appoints Lowell Giffhorn to be Chief Financial Officer
04 10월 2013 - 11:53PM
SpectraScience, Inc. (OTCQB:SCIE), a San Diego-based medical device
company, today announced that its board of directors has appointed
Lowell Giffhorn as the Company's new Chief Financial Officer.
Michael Oliver, President and Chief Executive Officer, said, "We
look forward to working with Lowell in growing our company and
moving to the next phase of our development – continued deployment
of systems in Europe and preparation of filings to gain PMA
approval of WavSTAT4 by the FDA in the US. Lowell brings years of
experience in finance, business operations, stockholder and
investor relations. He has been successful at a variety
of public companies."
Mr. Giffhorn, 66, has more than 30 years of experience with
public companies, including serving as CFO for Sym-Tek Systems,
Inc., Patriot Scientific Inc., Imagenetix, Inc., and Brendan
Technologies, Inc. Mr. Giffhorn received his MBA from
National University and his BS from the University of Illinois.
"It is an honor to join SpectraScience as Chief Financial
Officer and work towards positively impacting the cancer screening
and diagnostics industry," said Mr. Giffhorn. "I look forward to
working with Mike, the board of directors and the SpectraScience
team to increase the value of our Company for both our employees
and shareholders."
Forward Looking Statements
This news release contains forward-looking statements that
involve risks and uncertainties that may cause SpectraScience's
actual results to differ materially from results discussed in
forward-looking statements. Readers are urged to carefully review
and consider the various disclosures made by SpectraScience in this
news release, its most recent Form 10-K and in SpectraScience's
other reports filed with the Securities and Exchange Commission
("SEC") that attempt to advise interested parties of the risks and
factors that may affect SpectraScience's business. These
forward-looking statements are qualified in their entirety by the
cautions and risk factors filed by SpectraScience in its annual
report on Form 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that
designs, develops, manufactures and markets spectrophotometry
systems capable of determining whether tissue is normal,
pre-cancerous or cancerous without physically removing tissue from
the body. The WavSTAT™ Optical Biopsy System uses light to
optically scan tissue and provide the physician with an immediate
analysis. With FDA approval for sale in the U.S. and the CE Mark
for the European Union, the WavSTAT System is the first
commercially available product that incorporates this innovative
technology for clinical use. The Company's LUMA imaging technology
has received FDA approval for an optical non-invasive system that
is proven to more effectively detect cervical cancer precursors
than conventional methods available in the market today.
CONTACT: SpectraScience, Inc.
Michael Oliver,
President and Chief Executive Officer
(858) 847-0200
SpectraScience (CE) (USOTC:SCIE)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
SpectraScience (CE) (USOTC:SCIE)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024